Edition:
United States

Delcath Systems Inc (DCTH.O)

DCTH.O on Consolidated Issue listed on NASDAQ Capital Market

1.96USD
9 Dec 2016
Change (% chg)

-- (+0.00%)
Prev Close
$1.96
Open
$1.98
Day's High
$2.00
Day's Low
$1.88
Volume
59,779
Avg. Vol
110,713
52-wk High
$9.60
52-wk Low
$1.35

DCTH.O

Chart for DCTH.O

About

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System... (more)

Overall

Beta: 2.26
Market Cap(Mil.): $4.31
Shares Outstanding(Mil.): 2.20
Dividend: --
Yield (%): --

Financials

  DCTH.O Industry Sector
P/E (TTM): -- 30.70 30.40
EPS (TTM): -10.07 -- --
ROI: -112.21 13.28 15.24
ROE: -161.99 17.04 16.58

BRIEF-Delcath Q3 loss $0.66/shr

* Believes it has sufficient capital to fund its operating activities through end of 2017

Nov 11 2016

BRIEF-Delcath Systems issues letter to stockholders

* Assuming conditions are satisfied, expect anticipated qtrly releases throughout 2017 will fund clinical development plan through 2017-end Source text for Eikon: Further company coverage:

Oct 18 2016

BRIEF-Delcath Systems announces new clinical sites for FOCUS Phase 3 trial for ocular melanoma liver metastases

* Delcath Systems - 5 new clinical trial sites in U.S. have been activated in global FOCUS Phase 3 clinical trial for ocular melanoma liver metastases

Oct 11 2016

BRIEF-Delcath prices underwritten public offering at $3.00 per share

* Delcath prices underwritten public offering of common stock and warrants

Sep 30 2016

BRIEF-Delcath announces proposed public offering of common stock and warrants

* Delcath announces proposed public offering of common stock and warrants

Sep 29 2016

BRIEF-Delcath posts Q2 loss of $4.41/share

* Delcath believes it has sufficient capital to fund its operating activities through end of 2017 Source text for Eikon: Further company coverage:

Aug 16 2016

Earnings vs. Estimates